Zidesamtinib Drug Asset Due Diligence Report 2026

This Zidesamtinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Zidesamtinib can convert its Small molecule drug profile and ROS1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zidesamtinib (query alias: Zidesamtinib)
Modality / target	Small molecule drug; ROS1; ROS1 inhibitors
Highest global status	NDA/BLA
Originator	Nuvalent, Inc.
Active developers	Nuvalent, Inc.

The MCP disease footprint includes Reactive oxygen species 1 positive non-small cell lung cancer, Gangliosidosis, GM1, ROS1 positive Solid Tumors. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05118789	Phase 1/2	Recruiting	359	Maximum Tolerated Dose (MTD) (Phase 1)
JPRN-jRCT2031230693	Phase 1/2	Recruiting	45	Maximum tolerated dose (Phase 1): Highest dose with dose-limiting toxicity (DLT) rate =< 25% RP2D: To determine the RP2D Objective Response Rate (ORR) (Phase 2): To determine ORR as assessed by BICR
NCT06797362	Not Applicable	Available	Not disclosed	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Zidesamtinib efficacy and safety in patients with advanced ROS1-positive solid tumors other than NSCLC in the ARROS-1 study.

Phase 1/2; n=15; evaluation: Positive. Reported fields: ORR = 40.0 %

Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC

Phase 1/2; n=432; evaluation: Positive. Reported fields: -; ORR(BICR) = 51 % (95%CI, 37 - 65); ORR(BICR) = 44 % (95%CI, 34 - 53)

1256MO - Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours

Phase 1/2; n=104; evaluation: Positive. Reported fields: RP2D = 100 mg QD % ; RP2D = 100 mg QD % ; RP2D = 100 mg QD %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zidesamtinib addresses Reactive oxygen species 1 positive non-small cell lung cancer, Gangliosidosis, GM1, ROS1 positive Solid Tumors. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-06-09	GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year	NDA/BLA	US$8,524.4M stated total
2025-12-16	Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million	Phase 3	US$315.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO